Neuroprotection by deprenyl and other propargylamines: Glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B

Journal of Neural Transmission

Volumn 110, Issue 5, 2003, Pages 509-515

  Tatton, W ^a   Chalmers Redman, R ^a   Tatton, N ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Anti apoptosis; Deprenyl; GAPDH; Parkinson's disease

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; COPPER ZINC SUPEROXIDE DISMUTASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEAT SHOCK PROTEIN 70; PROTEIN BAX; PROTEIN BCL 2; PROTEIN C JUN; SELEGILINE;

APOPTOSIS; ENZYME INHIBITION; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL SURVIVAL; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MONOAMINE OXIDASE; NEURONS; NEUROPROTECTIVE AGENTS; PARGYLINE; PARKINSON DISEASE; PROPYLAMINES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-JUN; SELEGILINE; SUPEROXIDE DISMUTASE;

EID: 0037734329     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-002-0827-z     Document Type: Review

References (40)

1. Andringa G, Cools AR (2000) The neuroprotective effects of CGP 3466B in the best in vivo model of Parkinson's disease, the bilaterally MPTP-treated rhesus monkey. J Neural Transm [Suppl] 60: 215-225
2. Carlile GW, Chalmers-Redman RM, Tatton NA, Pong A, Borden KE, Tatton WG (2000) Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldchyde-3-phosphate dehydrogenase to a dimer [in process citation]. Mol Pharmacol 57: 2-12
3. Chiba K, Trevor A, Castagnoli N Jr (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120: 574-578
4. Cohen G, Spina MB (1989) Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 26: 689-690
5. Cohen G, Pasik P, Cohen B, Leist A, Mytilineau C, Yahr MD (1984) Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 106: 209-210
6. Crossman AR, Clarke CE, Boyce S, Robertson RG, Sambrok MA (1987) MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms. Can J Neurol Sci 14: 428-435
7. Del Zompo M, Piccardi MP, Ruiu S, Corsini GU, Vaccari A (1992) Characterization of a putatively vesicular binding site for [3H]MPP+ in mouse striatal membranes. Brain Res 571: 354-357
8. Dimonte DA, Wu EY, Delanney LE, Irwin I, Langston JW (1992) Toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes. J Pharmacol Exp Ther 261: 44-49
9. Fukuhara Y, Takeshima T, Kashiwaya Y, Shimoda K, Ishitani R, Nakashima K (2001) GAPDH knockdown rescues mesencephalic dopaminergic neurons from MPP+ - induced apoptosis. Neuroreport 12: 2049-2052
10. Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, Faucheux BA, Mouatt-Prigent A, Turmel H, Srinivasan A, Ruberg M, Evan GI, Agid Y, Hirsch EC (2000) Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA 97: 2875-2880
11. Hartmann A, Michel PP, Troadec JD, Mouatt-Prigent A, Faucheux BA, Ruberg M, Agid Y, Hirsch EC (2001) Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease? J Neurochem 76: 1785-1793
12. Holschneider DP, Chen K, Scif I, Shih JC (2001) Biochemical, behavioral, physiologic, and neurodevelopmental changes in mice deficient in monoamine oxidase A or B. Brain Res Bull 56: 453-462
13. Jenner P, Olanow CW (1996) Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47: S161-170
14. Kragten E, Lalande I, Zimmermann K, Roggo S, Schindler P, Muller D, van Oostrum J, Waldmeier P, Furst P (1998) Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. J Biol Chem 273: 5821-5828
15. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980
16. Lotharius J, O'Malley KL (2000) The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J Biol Chem 275: 38581-38588
17. Ma SY, Collan Y, Roytta M, Rinne JO, Rinne UK (1995) Cell counts in the substantia nigra: a comparison of single section counts and disector counts in patients with Parkinson's disease and in controls. Neuropathol Appl Neurobiol 21: 10-17
18. Mytilineou C, Cohen G (1985) Deprenyl protects dopamine neurons from neurotoxic effect of 1-methyl-4-phenylpyridinium ion. J Neurochem 45: 1951-1953
19. Nakamura K, Bindokas VP, Marks JD, Wright DA, Frim DM, Miller RJ, Kang UJ (2000) The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: the role of mitochondrial complex I and reactive oxygen species revisited. Mol Pharmacol 58: 271-278
20. Nicklas WJ, Yougster SK, Kindt MV, Heikkila RE (1987) MPTP, MPP+ and mitochondrial function. Life Sci 40: 721-729
21. Olanow CW (1993) A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease. Mov Disord 8: S1-7
22. Olanow CW, Tatton WG (1999) Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 22: 123-144
23. The Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328: 176-183
24. Paterson IA, Zhang D, Warrington RC, Boulton AA (1998) R-Deprenyl and R-2-Heptyl-N-methylpropargylamine prevent apoptosis in cerebellar granule neurons induced by cytosine arabinoside but not low extracellular potassium. Neurochem 70: 515-5523
25. Peter D, Jimenez J, Liu Y, Kim J, Edwards RH (1994) The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors. J Biol Chem 269: 7231-7237
26. Pifl C, Schingnitz G, Hornykicwicz O (1988) The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease. Neurosci Lett 92: 228-233
27. Pifl C, Giros B, Caron MG (1993) Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J Neurosci 13: 4246-4253
28. Reed JC (2002) Apoptosis-based therapies. Nature Rev - Drug Discovery 1: 111-121
29. Shashidharan P, Chalmers-Redman RM, Carlile GW, Rodic V, Gurvich N, Yuen T, Tatton WG, Sealfon SC (1999) Nuclear translocation of GAPDH-GFP fusion protein during apoptosis. Neuroreport 10: 1149-53
30. Tatton NA (2000) Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol 166: 29-43
31. Tatton NA, Rideout HJ (1999) Confocal microscopy as a tool to examine DNA fragmentation, Chromatin condensation and other apoptotic changes in Parkinson's disease. Parkinsonism Rel Disord 5: 179-186
32. Tatton NA, Maclean-Fraser A, Tatton WG, Perl DP, Olanow CW (1998) A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann Neurol 44: S142-148
33. Tatton WG, Ju WY, Holland DP, Tai C, Kwan M (1994) (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis, J Neurochem 63: 1572-1575
34. Tatton WG, Chalmers-Redman RM, Elstner M, Leesch W, Jagodzinski FB, Stupak DP, Sugrue MM, Tatton NA (2000) Glyceraldehyde-3-phosphate dehydrogenase in neurodegeneration and apoptosis signaling. J Neural Transm [Suppl] 60: 77-100
35. Tatton WG, Chalmers-Redman RME, Ju WJH, Carlile GW, Mammen M, Tatton NA (2002) Propargylamines induce anti-apoptotic new protein synthesis in serum and NGF withdrawn NGF-differentiated PC12 cells. J Pharmacol Exp Ther 301: 753-764
36. Wadia JS, Chalmers-Redman RME, Ju WJH, Carlile GW, Phillips JL, Fraser AD, Tatton WG (1998) Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (-)-deprenyl. J Neurosci 18: 932-947
37. Waldmeier PC, Boulton AA, Cools AR, Kato AC, Tatton WG (2000a) Neurorescuing effects of the GAPDH ligand CGP 3466B. J Neural Transm [Suppl] 60: 197-214
38. Waldmeier PC, Spooren WP, Hengerer B (2000b) CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 362: 526-537
39. Zhang D, Berry MD, Paterson IA, Boulton AA (1999) Loss of mitochondrial membrane potential is dependent on the apoptotic program activated: prevention by R-2HMP. J Neurosci Res 58: 248-292
40. Zimmerman K, Waldmeier PC. Tatton WG (1999) Dibenzoxepines as treatments for neurodegenerative diseases. Pure Appl Chem 71: 2039-2046